Zoetis Inc. (NYSE:ZTS) will release earnings for its fourth quarter before the opening bell on Thursday, Feb. 12.Analysts expect the Parsippany, New Jersey-based company to report quarterly earnings at $1.4 per share, compared to $1.4 per share in the year-ago period. The consensus estimate for Zoetis quarterly revenue is $2.36 billion (it reported $2.32 billion last year), according to Benzinga Pro.On Dec. 16, Zoetis announced pricing of $1.75 billion convertible senior notes offering.Shares of Zoetis rose ...

Core Viewpoint - Zoetis Inc. is expected to report stable earnings and revenue for its fourth quarter, with analysts projecting earnings per share to remain at $1.4 and revenue to increase slightly to $2.36 billion from $2.32 billion in the previous year [1][2]. Financial Performance - The anticipated earnings per share for Zoetis in the fourth quarter is $1.4, consistent with the same period last year [1]. - The consensus estimate for quarterly revenue is $2.36 billion, reflecting a growth from $2.32 billion reported in the previous year [1]. Recent Developments - On December 16, Zoetis announced the pricing of a $1.75 billion convertible senior notes offering, indicating a significant capital-raising effort [1]. - Shares of Zoetis rose by 0.4%, closing at $128.67 on Wednesday, suggesting a positive market response [2].

Core Insights - Zoetis, Inc. (ZTS) is anticipated to exceed expectations in its fourth-quarter 2025 earnings report, scheduled for February 12, 2026, with revenue estimates at $2.37 billion and earnings per share (EPS) at $1.40 [1][5] Group 1: Revenue Expectations - The Zacks Consensus Estimate for U.S. segment revenues is projected at $1.27 billion, likely reflecting a decrease from the previous year due to lower sales of companion animal products [3][5] - International segment revenues are expected to rise to $1.06 billion, driven by increased sales of companion animal products [4][5] Group 2: Product Performance - Sales of companion animal products, particularly from the parasiticides portfolio (including Simparica and Revolution) and key dermatology products (Apoquel and Cytopoint), are expected to contribute positively to revenues in both U.S. and International segments [7] - However, sales of monoclonal antibody products for osteoarthritis pain (Librela for dogs and Solensia for cats) are anticipated to decline in the U.S. due to concerns over side effects, potentially offsetting gains from other product categories [8] Group 3: Regulatory Developments - The FDA approved a new indication for Zoetis' Simparica Trio in 2025, which is expected to enhance sales by preventing flea tapeworm infections in dogs [10] Group 4: Historical Performance - Zoetis has a strong earnings surprise history, having surpassed estimates in each of the last four quarters with an average surprise of 5.37% [13]

Wall Street analysts forecast that Zoetis (ZTS) will report quarterly earnings of $1.40 per share in its upcoming release, pointing to no change from the year-ago quarter. It is anticipated that revenues will amount to $2.37 billion, exhibiting an increase of 2.1% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of thei ...

Zoetis (NYSE: ZTS) tanked after its November earnings release. Will history repeat itself pre-market on Feb. 12, when the animal healthcare company releases results for the fourth quarter of 2025? That's the question on the minds of many investors, less than a week before its earnings report hits the street. Whether the stock rallies after earnings or falls further afterward may depend on how closely the guidance updates align with current expectations. Fortunately for Zoetis, with expectations already wa ...

Company Performance - Pelican Bay Capital Management (PBCM) reported a return of 8.5% for its Concentrated Value Strategy in Q4 2025, outperforming the Russell 1000 Value Index, which returned 3.8% [1] - For the full year, the Strategy achieved a return of 20.6%, compared to 15.9% for the Index [1] - The strong performance was attributed to AI-related stocks and commodities exposure [1] Company Addition - PBCM highlighted Zoetis Inc. (NYSE:ZTS) as a new addition to its portfolio [2] - Zoetis Inc. focuses on animal health medications, vaccines, and diagnostic products, with a market capitalization of approximately $56.165 billion [2] - As of February 4, 2026, Zoetis Inc. stock closed at $126.73 per share, with a -0.35% return in the past month and a decline of 26.07% over the past twelve months [2] Industry Insights - The global animal health market was valued at approximately $50 billion last year and is expected to grow at a rate of 5-6% per year over the next decade [3] - Growth in the animal health market is driven by trends such as pets living longer and increasing acceptance of medicines and vaccines by pet owners [3] - PBCM initiated new positions in Zoetis Inc., along with AECOM (ACM) and FactSet Research (FDS), indicating a strategic focus on high-quality companies in the animal health sector [3]

Core Viewpoint - Zoetis Inc. is a leading animal health company facing challenges in stock performance and revenue growth due to various market and company-specific factors [2][5]. Company Overview - Zoetis Inc. has a market capitalization of $56.3 billion and specializes in animal health products, including medicines, vaccines, and diagnostic solutions for both livestock and companion animals [1]. Stock Performance - Over the past 52 weeks, Zoetis shares have decreased by 27.5%, underperforming the S&P 500 Index, which gained 12.2% during the same period [2]. - Year-to-date, Zoetis shares have gained 1.3%, contrasting with a slight decline in the S&P 500 Index [2]. Competitive Analysis - Zoetis has also lagged behind the State Street Health Care Select Sector SPDR ETF, which has seen a 5.4% increase over the past year [3]. Financial Performance - In Q3 2025, Zoetis reported revenue of approximately $2.4 billion, reflecting a modest year-over-year increase of about 1% [6]. - Analysts project a 7.1% year-over-year growth in EPS for the fiscal year 2025, estimating it to reach $6.34 [6]. Analyst Ratings - The consensus rating among 17 analysts covering Zoetis is a "Moderate Buy," with eight "Strong Buy" ratings, one "Moderate Buy," and eight "Holds" [6]. - This rating configuration has become less bullish compared to three months ago, when there were 11 "Strong Buy" ratings [7]. Recent Downgrade - On January 22, 2026, Piper Sandler analyst David Westenberg downgraded Zoetis from "Overweight" to "Neutral" and reduced the price target from $190 to $135 [7].

Company Overview - Zoetis (ZTS) is expected to report flat earnings of $1.40 per share for the quarter ended December 2025, with revenues projected at $2.37 billion, reflecting a 2.1% increase from the previous year [3]. Earnings Expectations - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - A positive Earnings ESP of +0.84% suggests that analysts are optimistic about Zoetis's earnings prospects, although the company holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Zoetis exceeded the expected earnings of $1.62 per share by delivering $1.70, resulting in a surprise of +4.94% [13]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [14]. Industry Context - In comparison, Neurocrine Biosciences (NBIX) is expected to post earnings of $2.25 per share for the same quarter, marking a significant year-over-year increase of +125%, with revenues anticipated to rise by 25% to $784.42 million [18].

Group 1 - Zoetis (ZTS) stock decreased by 2.02% to $122.41, underperforming the S&P 500, which fell by 0.84% [1] - Prior to the recent trading session, Zoetis shares had declined by 3.42%, lagging behind the Medical sector's gain of 0.16% and the S&P 500's gain of 1.8% [1] Group 2 - The upcoming earnings report for Zoetis is scheduled for February 12, 2026, with projected earnings per share (EPS) of $1.4, indicating no change from the same quarter last year [2] - Revenue is estimated to be $2.37 billion, reflecting a 2.08% increase compared to the same quarter of the previous year [2] Group 3 - For the full year, analysts expect earnings of $6.34 per share and revenue of $9.45 billion, representing changes of +7.09% and 0%, respectively, from last year [3] Group 4 - Recent adjustments to analyst estimates for Zoetis are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] Group 5 - Changes in estimates are directly related to stock price performance, and the Zacks Rank system incorporates these changes to provide a rating system [5] Group 6 - Zoetis currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 18.36, which is a premium compared to the industry average Forward P/E of 17.2 [6] Group 7 - The company has a PEG ratio of 2.16, while the Medical - Drugs industry has an average PEG ratio of 1.15 [7] - The Medical - Drugs industry is ranked 159 in the Zacks Industry Rank, placing it in the bottom 36% of over 250 industries [7] Group 8 - The Zacks Industry Rank evaluates the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) is currently viewed as a better value opportunity compared to Zoetis (ZTS) based on various financial metrics and analyst outlooks [1]. Valuation Metrics - SGIOY has a forward P/E ratio of 13.68, while ZTS has a forward P/E of 18.36, indicating that SGIOY may be undervalued relative to ZTS [5]. - The PEG ratio for SGIOY is 2.05, compared to ZTS's PEG ratio of 2.16, suggesting that SGIOY offers a more favorable valuation when considering expected earnings growth [5]. - SGIOY's P/B ratio stands at 1.78, significantly lower than ZTS's P/B ratio of 10.26, further supporting the notion that SGIOY is undervalued [6]. Analyst Outlook - SGIOY holds a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to ZTS, which has a Zacks Rank of 3 (Hold) [3]. - The improving earnings outlook for SGIOY enhances its attractiveness as a value investment [7].